广东广康生化科技股份有限公司 证券代码：300804 证券简称：广康生化 公告编号：2026-002 一、股东减持情况 （一）股东减持股份情况 关于特定股东减持股份计划期限届满暨实施情况的公告 股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合伙）保证向本公司 提供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 广东广康生化科技股份有限公司（以下简称"公司"）于 2025 年 10 月 15 日在 巨潮资讯网（www.cninfo.com.cn）披露了《关于特定股东减持股份预披露公告》（公 告编号：2025-048），公司股东共青城瑞宏凯银壹号股权投资基金合伙企业（有限合 伙）（以下简称"瑞宏凯银壹号"）计划于减持计划公告之日起三个交易日后的三个 月内（即 2025 年 10 月 18 日-2026 年 1 月 17 日）以集中竞价交易或大宗交易方式减 持公司股份累计不超过 1,980,000 股，即不超过本公司总股本的 2.6757%。 截至 2026 年 1 月 17 日，上述减持计划期限已届满。公司已收到上述股东发来的 ...

Core Insights - The expiration of the compound patent for Pyraclostrobin in China has led to a surge in domestic interest, with companies increasing registration, production, and promotion efforts [1][6] - As of 2024, there are 62 registered Pyraclostrobin products in China, including 32 active ingredients and 30 formulations, primarily targeting wheat and peanut crops [1][6] - The global market for Pyraclostrobin has seen significant growth, with sales expected to rise from $973 million in 2015 to $2.014 billion by 2024, and projected to reach $2.172 billion by 2025 [5][11] Industry Overview - Pyraclostrobin, developed by Bayer in 2004, is a broad-spectrum fungicide known for its low toxicity and effectiveness against various plant diseases [2][3] - It is particularly effective against diseases affecting cereals and legumes, making it a key product in the global fungicide market, holding an 8% market share [3][5] Market Dynamics - The Chinese market for Pyraclostrobin is expanding rapidly due to the high incidence of wheat diseases, particularly Fusarium head blight, which can cause yield losses of 10% to 20% in epidemic years [7][11] - The area affected by Fusarium head blight in China is projected to reach 15 million acres in 2024, an increase of 6 million acres from 2023 [7][8] Competitive Landscape - Major companies in the Pyraclostrobin sector include Hailir, Anhui Jiuyi, Nantong Taihe, and Guangdong Guokang, among others, with many expanding production capacity [9][10] - Hailir reported a revenue of 3.391 billion yuan in the first nine months of 2025, a 5.5% increase year-on-year, indicating strong market performance [10] Future Trends - The demand for Pyraclostrobin is expected to continue rising due to increasing occurrences of wheat diseases and advancements in application methods [11] - The market is becoming increasingly competitive, with potential oversupply leading to price fluctuations, necessitating companies to optimize production and enhance brand presence [12] - The trend towards formulation mixtures is anticipated to grow, as combining Pyraclostrobin with other chemicals can delay resistance development and enhance efficacy [13]

中国经济网北京1月13日讯 广康生化(300804.SZ)1月9日发布关于公司及相关人员收到广东证监局警 示函的公告。 2023年6月27日，广康生化在深交所创业板上市，发行数量为1,850.00万股，占发行后总股本的 25.00%，本次发行全部为新股，发行价格为42.45元/股。目前该股处于破发状态。 广康生化发行募集资金总额为78,532.50万元，扣除不含税发行费用后，实际募集资金净额为 69,736.57万元。广康生化实际募资净额比原拟募资多617.79万元。公司2023年6月19日披露的招股说明 书显示，广康生化拟募集资金69,118.78万元，用于年产4500吨特殊化学品建设项目、补充流动资金。 广康生化发行的保荐机构为华泰联合证券有限责任公司，保荐代表人为张新星、刘恺。公司本次发 行费用总额为8,795.93万元，其中华泰联合证券有限责任公司获得承销及保荐费用6,582.60万元。 (责任编辑：华青剑) 2023年7月至2025年8月期间，公司经相关审议程序通过使用募集资金进行现金管理的议案后，循环 使用募集资金滚动购买179笔理财产品，经查，其中有158笔为非保本理财产品，2023年、2024 ...

Group 1 - China Shipbuilding Defense expects a net profit of 940 million to 1.12 billion yuan for 2025, an increase of 149.61% to 196.88% year-on-year [1] - China First Heavy Industries has only undertaken a small number of related accessory projects and has not generated revenue from them [2] - Huanyu Electronics plans to invest 30 million yuan in a private equity fund focused on AI and emerging industries [3] Group 2 - Zhixiang Jintai's GR1803 injection has been included in the priority review list by the National Medical Products Administration [4] - JianKai Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [5] - Debon Holdings will continue to suspend trading from January 12 due to significant matters being planned [6] Group 3 - South Network Technology's shareholder intends to transfer 847.05 million shares, accounting for 1.50% of the total share capital [7] - Hengrui Medicine has received approval for clinical trials of four drugs [8] - Daotong Technology expects a net profit of 900 million to 930 million yuan for 2025, a year-on-year increase of 40.42% to 45.10% [10] Group 4 - Betta Pharmaceuticals has invested 50 million yuan to acquire a 20% stake in Hangzhou Zhixing Pharmaceutical [11] - Tianyu Biology reported a 10.38% year-on-year decline in cumulative sales revenue for 2025 [12] - Lifang Pharmaceutical's subsidiary has obtained a drug registration certificate for a pain relief product [13] Group 5 - R&F Properties reported a total sales revenue of approximately 14.21 billion yuan for 2025 [14] - Wanfu Biology expects a net profit decline of 87.71% to 91.81% for 2025 [15] - Dazhi expects a negative net profit for 2025 [16] Group 6 - Dongzhu Ecology is negotiating to terminate the acquisition of control over a satellite communication company [17] - Baotai has received a milestone payment of 10 million USD from Hikma Pharmaceuticals [18] - Huace Navigation expects a net profit of 670 million to 690 million yuan for 2025, a year-on-year increase of 14.84% to 18.27% [19] Group 7 - Shenzhen Gas reported a net profit decline of 3.45% for 2025 [20] - Baogang Co. plans to adjust the price of rare earth concentrate for Q1 2026 to 26,834 yuan per ton [21] - Jiuding Investment expects to report a loss for 2025 [22] Group 8 - Shanghai Pharmaceuticals has received a drug registration certificate for a treatment for myasthenia gravis [23] - Hualan Biological plans to acquire a 35% stake in Guangfeng Capsule [24] - Ruina Intelligent plans to invest 169.9 million yuan in a new R&D production base for heat pumps [25] Group 9 - Wantong Development expects to report a loss for 2025 [26] - Xianghe Industrial has completed the purchase of a 5% stake in Hezhixiang Technology [27] - Guangkang Biochemical received a warning letter from the Guangdong Securities Regulatory Commission [28] Group 10 - Xiaoming Co. reported a 37.07% year-on-year decline in chicken product sales revenue for December 2025 [29] - Luokai Co. won a procurement project from State Grid Fujian Power worth approximately 48.2 million yuan [30] - Minhe Co. reported a 65.22% year-on-year increase in the sales of commodity chick seedlings for December 2025 [31] Group 11 - Zhenghai Biological has obtained a registration certificate for calcium silicate bio-ceramic materials [32] - Three Gorges Energy reported a 5.99% year-on-year increase in cumulative total power generation for 2025 [33] - Huisheng Biological expects a net profit of 235 million to 271 million yuan for 2025 [34] Group 12 - Maihe Co. announced the release of the detention measures against its chairman [35] - Wandong's Alzheimer's project has been included in a national major special project for innovative drug development [36] - Kangxin New Materials plans to transfer forest land assets with a book value of 1.203 billion yuan [37] Group 13 - Greenland Holdings expects a net loss of 16 billion to 19 billion yuan for 2025 [39] - Zhongxin Fluorine Materials has obtained a pesticide production license [40]

Core Viewpoint - Guangkang Biochemical (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper use of raised funds for cash management, specifically concerning the purchase of non-principal guaranteed financial products [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. [2025] 179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company used raised funds to purchase 179 financial products [1] Group 2: Financial Product Purchases - Out of the 179 financial products purchased, 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases was as follows: 14 in 2023, 68 in 2024, and 76 in 2025 [1] Group 3: Disclosure Issues - The company failed to adequately disclose the risks associated with purchasing non-principal guaranteed financial products in its annual reports [1] - Despite not incurring any principal losses, the company's actions did not comply with regulatory requirements outlined in the "Regulatory Guidelines for Listed Companies on the Management and Use of Raised Funds" [1]

Core Viewpoint - Guangkang Biotech (300804.SZ) received a warning letter from the Guangdong Securities Regulatory Bureau regarding the improper management of raised funds, specifically concerning the purchase of non-principal guaranteed financial products without adequate disclosure of associated risks [1] Group 1: Regulatory Actions - The company was issued a warning letter (Decision No. 〔2025〕179) by the Guangdong Securities Regulatory Bureau [1] - The investigation covered the period from July 2023 to August 2025, during which the company engaged in cash management using raised funds [1] Group 2: Fund Management Practices - The company executed 179 transactions to purchase financial products, of which 158 were non-principal guaranteed products [1] - The breakdown of non-principal guaranteed product purchases includes 14 in 2023, 68 in 2024, and 76 in 2025 [1] - The company failed to adequately disclose the risks of potential principal loss in its annual reports regarding the use of raised funds [1] Group 3: Compliance Violations - The company's actions were found to be non-compliant with the regulatory requirements outlined in the "Guidelines for the Supervision of Listed Companies on the Management and Use of Raised Funds" [1] - Violations included not fully disclosing the safety of principal when using raised funds for cash management [1]

广康生化公告，公司因在2023年7月至2025年8月期间，循环使用募集资金滚动购买179笔理财产品，其 中有158笔为非保本理财产品，且在相应年度《募集资金存放与使用专项报告》中未充分披露使用募集 资金进行现金管理的本金安全性问题，收到广东证监局出具的警示函。 ...

广东广康生化科技股份有限公司（以下简称"公司"）于近日收到中国证券监督 管理委员会广东监管局（以下简称"广东证监局"）出具的《关于对广东广康生化科 技股份有限公司、蔡丹群、陈海霞采取出具警示函措施的决定》（〔2025〕179 号） （以下简称"《警示函》"）。现将具体情况公告如下： 一、《警示函》的内容 "广东广康生化科技股份有限公司、蔡丹群、陈海霞： 根据《上市公司现场检查规则》(证监会公告〔2025〕5 号)等规定，我局近期 对广东广康生化科技股份有限公司（以下简称广康生化或公司）进行了现场检查， 发现公司存在以下问题： 证券代码：300804 证券简称：广康生化 公告编号：2026-001 广东广康生化科技股份有限公司 关于公司及相关人员收到广东证监局警示函的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二款第一项的规定，违反了《上市公司信息披露管理办法》（证监会令第 182 号， 下同）第三条第一款的规定。 公司及相关人员收到《警示函》后，对函件中指出的问题高度重视，并将认真吸 取教训、深入反思，严格落实整改措施，切实加强对《上市公司信息披露管 ...

（文章来源：证券日报） 证券日报网讯 12月24日，广康生化发布公告称，公司第四届董事会第四次会议审议通过《关于使用自 有资金支付募投项目部分款项并以募集资金等额置换的议案》。 ...

每经AI快讯，广康生化（SZ 300804，收盘价：35.05元）12月24日晚间发布公告称，公司第四届第四次 董事会会议于2025年12月23日以通讯表决方式召开。会议审议了《关于使用自有资金支付募投项目部分 款项并以募集资金等额置换的议案》等文件。 2024年1至12月份，广康生化的营业收入构成为：农药占比99.84%，其他业务占比0.16%。 截至发稿，广康生化市值为26亿元。 每经头条（nbdtoutiao）——左手"欠款"右手"豪购"！杨陵江收购"国内酒庄第一股"，1919是否重启上 市？"吹太多牛都实现了，但千亿还没实现，我很着急" （记者 曾健辉） ...